StreetInsider.com News Articles

Sutro Biopharma doses first patient in Phase 1 trial of STRO-006 ADC

Wed, 21 Oct 2026 08:02:05 -0400

Sutro Biopharma (NASDAQ: STRO) announced that the first patient has been dosed in a Phase 1 trial of STRO-006, an antibody-drug conjugate (ADC) targeting integrin β6 (ITGB6), in adults with advanced or metastatic solid tumors.

STRO-006 is a DAR8 ADC that delivers an exatecan payload via a site-specific β-glucuronidase cleavable linker. The drug targets ITGB6, an antigen expressed across several solid tumor types, including non-small cell lung cancer, head and neck cancer, esophageal and gastric cancer, colorectal cancer, endometrial cancer, urothelial cancer, and breast cancer.

The open-label, multicenter dose-escalation trial will evaluate the safety, pharmacokinetics, and preliminary anti-tumor activity of STRO-006, beginning

Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors

Wed, 21 Oct 2026 08:00:00 -0400

— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year —

— Initial clinical data expected in the second half of 2027 —

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase 1 trial of STRO-006 in patients with a range of solid tumors. STRO-006 is the Company’s potential best-in-class integrin β6 (ITGB6)-targeting exatecan

Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors

Wed, 21 Oct 2026 08:00:00 -0400

— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year —

— Initial clinical data expected in the second half of 2027 —

H.C. Wainwright Reiterates Buy Rating on Sutro Biopharma (STRO)

Fri, 16 Oct 2026 08:08:32 -0400

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $50.00 price target on Sutro Biopharma (NASDAQ: STRO).

The analyst commented: "Sutro’s World ADC presentations gave us an opportunity to revisit a central question for Sutro which remains how much can better ADC design improve what these drugs deliver for patients? Across early clinical findings and preclinical studies, the company explored whether keeping payloads attached longer, combining different mechanisms, and adjusting their ratios could improve tolerability and sustain activity as tumors become resistant. While much of the work remains preclinical and some findings were previously disclosed, we believe the collective dataset

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

Mon, 12 Oct 2026 08:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced its participation at the 17th Annual World ADC Conference, taking place in San Diego, October 12-15, 2026.

“Sutro's presence at World ADC this year reflects meaningful progress across our pipeline, from a plenary presentation on the early clinical safety and pharmacokinetic profile of STRO-004 to new preclinical insights on STRO-006 and our first wholly-owned dual-payload ADC, STRO-227,” said Hans-Peter Gerber, Ph.D., Sutro's Chief Scientific

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

Mon, 12 Oct 2026 08:00:00 -0400

Wells Fargo Assumes Sutro Biopharma (STRO) at Overweight

Wed, 30 Sep 2026 06:23:22 -0400

Wells Fargo analyst Yanan Zhu assumes coverage on Sutro Biopharma (NASDAQ: STRO) with a Overweight rating and a price target of $49.00.

For an analyst ratings summary and ratings history on Sutro Biopharma click here. For more ratings news on Sutro Biopharma click here.

Shares of Sutro Biopharma closed at $16.10 yesterday.

Sutro Biopharma names new SVP of business development

Tue, 29 Sep 2026 08:01:07 -0400

Sutro Biopharma, Inc. (NASDAQ: STRO) has appointed Lucas Donigian as Senior Vice President, Business Development, effective September 28, 2026, according to a company statement.

Donigian brings more than 20 years of biotechnology industry experience in business development, corporate strategy, and alliance management. The company said he has executed oncology partnerships with an aggregate deal value of over $2 billion, including in the antibody drug conjugate (ADC) space.

Donigian most recently served as Vice President, Head of Business Development & Licensing and Commercial at Zymeworks Inc., where he led the execution of a licensing agreement with Jazz Pharmaceuticals for zanidatamab. Before that, he

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

Tue, 29 Sep 2026 08:00:00 -0400

SOUTH SAN FRANCISCO, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Lucas Donigian as Senior Vice President, Business Development, effective September 28, 2026. Mr. Donigian brings more than 20 years of biotechnology industry experience, with a background in business development, corporate strategy, and alliance management. He has a demonstrated history of executing high-value oncology partnerships, including in the ADC space, with an aggregate deal value of over $2 billion.

“We are thrilled

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

Tue, 29 Sep 2026 08:00:00 -0400

“We are thrilled

Form 4 SUTRO BIOPHARMA, INC. For: Sep 18 Filed by: Gerber Hans-Peter

Tue, 22 Sep 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260922/27091131.html

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'